You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AR-positive metastatic breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

Recruiting
  • Breast Cancer
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Oct 18, 2022

Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial

Not yet recruiting
  • Hormone Receptor-positive Breast Cancer
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Oct 5, 2022

Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

Recruiting
  • Advanced Breast Carcinoma
  • +17 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)

Recruiting
  • Triple Negative Breast Cancer
  • +5 more
  • Manchester, Greater Manchester, United Kingdom
  • +6 more
Jan 5, 2023

Androgen Receptor Positive, Estrogen Receptor Negative, HER2/Neu Negative Trial in United States (drug, other, biological)

Active, not recruiting
Has Results
  • Androgen Receptor Positive
  • +5 more
  • Corona, California
  • +6 more
Jun 8, 2022

Breast Cancer Trial in United States (bicalutamide, diagnostic laboratory biomarker analysis, immunohistochemistry staining

Completed
Has Results
  • Breast Cancer
  • San Francisco, California
  • +7 more
Jul 8, 2022

Metastatic Triple Negative Breast Cancer Trial in Guangzhou (TPC, Bicalutamide 150 mg)

Terminated
  • Metastatic Triple Negative Breast Cancer
  • TPC
  • Bicalutamide 150 mg
  • Guangzhou, Guangdong, China
  • +1 more
Jan 26, 2021

Metastatic Breast Cancer Trial in United States (Enzalutamide, Mifepristone, TPC)

Recruiting
  • Metastatic Breast Cancer
  • Birmingham, Alabama
  • +5 more
Oct 19, 2023

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

Metastatic Breast Cancer Trial in United States (Orteronel)

Completed
Has Results
  • Metastatic Breast Cancer
  • New Haven, Connecticut
  • +9 more
Jun 8, 2022

Metastatic Breast Cancer (MBC) Trial in United States (Palbociclib, Bicalutamide)

Active, not recruiting
  • Metastatic Breast Cancer (MBC)
  • Basking Ridge, New Jersey
  • +4 more
Oct 31, 2022

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 12, 2023

Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

Not yet recruiting
  • Breast Cancer
  • Dalpiciclib combined with Letrozole
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Aug 3, 2023

Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

Not yet recruiting
  • Estrogen-receptor-positive Breast Cancer
  • +3 more
  • elacestrant, palbociclib, abemaciclib, ribociclib
  • Chicago, Illinois
    Northwestern University
Sep 25, 2023

HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Discontinuation of Anti-HER-2 Maintenance Treatment
  • Miami, Florida
    University of Miami
Jul 17, 2023

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 10, 2022

HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)

Active, not recruiting
  • HER2-positive Breast Cancer
  • Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Jan 30, 2023

Hormone Receptor-positive Breast Cancer Trial in Tampa (Cemiplimab, Capecitabine)

Recruiting
  • Hormone Receptor-positive Breast Cancer
  • Tampa, Florida
    Moffitt Cancer Center
Dec 30, 2022

Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

Recruiting
  • Metastatic Breast Cancer
  • +2 more
  • Ocala, Florida
    Ocala Oncology Center PL DBA Florida Cancer Affiliates
Jul 19, 2023

A Real-world Study of Inetetamab for First-line Treatment of MBC

Not yet recruiting
  • Breast Cancer
  • Real-world Study
  • (no location specified)
Aug 6, 2023